Background Magnesium sulphate was introduced for fetal neuroprotection in Australia in
2010. The aim of this study was to determine how often antenatal magnesium sulphate is …

Background It is important to establish whether research recommendations regarding
magnesium sulphate for neuroprotection can be readily translated into clinical practice and …

Antenatal magnesium sulphate reduces the risk of cerebral palsy in babies born< 30 weeks'
gestation. A guideline for its use in women at imminent risk of preterm birth was …

Background Australian and New Zealand clinical practice guidelines, endorsed by the
NHMRC in 2010, recommend administration of antenatal magnesium sulphate to women at …

Objective The objective is to provide guidelines for the use of antenatal magnesium sulphate
for fetal neuroprotection of the preterm infant. Options Antenatal magnesium sulphate …

Background Babies born preterm are at an increased risk of dying in the first weeks of life,
and those who survive have a higher rate of cerebral palsy (CP) compared with babies born …

Background Clinical practice guidelines recommend the use of antenatal magnesium
sulphate for fetal neuroprotection before preterm birth at< 30 weeks' gestation. Aims This …

METHODS OF STUDY SELECTION: Randomized controlled trials comparing magnesium
sulfate with placebo/other treatment in patients at risk of preterm delivery were evaluated for …

Background Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …

Despite improvements in perinatal care, preterm birth still occurs regularly and the
associated brain injury and adverse neurological outcomes remain a persistent challenge …